Oncoheroes Biosciences

📢 Exciting News!

Our co-founder, Cesare Spadoni, is participating in the EFGCP - European Forum for Good Clinical Practice Better Medicines for Children Conference 2024 in Brussels on Tuesday, October 22! Meet Cesare there as he joins the panel discussing “Paediatric-only Drug Development / First-in-Child Companies.”

Representing Oncoheroes Biosciences, a biotech exclusively focused on developing new therapies for childhood cancer, Cesare will address the unique challenges in pediatric drug development and the critical need for innovative solutions to ensure children have access to safe and effective treatments.

🔗 https://efgcp.eu/event?title=EFGCP-Better-Medicines-for-Children-Conference-2024

We’re thrilled to announce that Dr. Raphaël Rousseau, MD, PhD, is joining Oncoheroes Biosciences' board of directors! Raphaël’s appointment is a significant endorsement from a leading industry expert in the pediatric cancer field.

He is a pivotal addition to our team, helping to shape the future of Oncoheroes' mission to develop new therapies for childhood cancer.

"I’m excited to join Oncoheroes and help bring new treatments to children with cancer faster. Because they can't wait any longer!" states Raphaël Rousseau.

Welcome to the team, Raphaël! We can’t wait to make a difference together. 🎗️

September is here, kicking off Childhood Cancer Awareness Month!

Oncoheroes Biosciences is proud to once again sponsor CureFest in Washington, DC.

As a biotech exclusively focused on developing new therapies for childhood cancer, there’s nowhere else we’d rather be.

CureFest for Childhood Cancer is where our community comes together—families, researchers, and advocates—each with a fierce dedication to changing the game for young cancer fighters. We’re honored to stand with them, pushing for real progress that makes a difference.

Join CureFest in DC on September 22-24 as we rally for a brighter future for these brave kids. Together, we can make it happen. 🎗️

We’re excited to share some incredible news! 🎗️

Oncoheroes Biosciences is the benefactor of the recent Battlecorn Care Packages, a foundation created in honor of Jaycee Vallier. 💛

Thanks to the generous grant from this event, we’re now closer to launching the international clinical trial for our lead compound, volasertib, testing its efficacy in five types of pediatric cancer.

“Each year we choose a benefactor to receive the efforts of our yearly fundraising in support of research in pediatric cancer. This year we chose Oncoheroes because of their dedication to creating better treatment options for our kids in a space where our government and pharmaceutical industry don’t seem to care. We feel this investment into the future will put our community, our warriors, and our families on a path to better treating and one day eliminate childhood cancers”, explains Curtis Vallier, Chief Operating Officer at Battlecorn Care Packages and Jaycee’s dad.

This announcement is especially meaningful as we celebrate Childhood Cancer Awareness Month. We’re grateful for the support of Battlecorn Care Packages, helping us move forward in our mission of finding new therapies for childhood cancer.

Together, we’re making strides towards a brighter future for kids battling cancer.



Thank you, BattleCorn Care Packages, for your incredible support!

🔗 https://oncoheroes.com/insights-news-1/20240910/battlecorncarepackagesoh

As we kick off Childhood Cancer Awareness Month, we're thrilled to share a major milestone in our fight against childhood cancer!

Oncoheroes Biosciences has secured exclusive worldwide pediatric oncology rights for dovitinib from Novartis. The opportunity to explore this potential option for pediatric cancer treatment marks a significant step forward in our mission to bring new hope to young patients.

With clinical trials on the horizon, we’re eager to investigate how dovitinib can make a difference for children facing bone sarcomas and other challenging pediatric cancers.

Let’s continue to push boundaries and bring innovative treatments to those who need them most.

🔗 https://oncoheroes.com/press-releases-content/2024/dovitinib-new-agreement

Brain tumors are the leading cause of cancer-related deaths in children. In the US alone, nearly 4,600 children and teenagers are diagnosed with a brain tumor each year.

Despite advancements in medical science, survival rates for certain types of pediatric brain tumors remain stubbornly low, with only around 70% of children surviving five years post-diagnosis. There's an urgent need to improve treatments for kids and teenagers diagnosed with brain tumors. At Oncoheroes Biosciences, we're committed to finding better treatments for children diagnosed with cancer, including brain tumors.

This month, we're joining the movement to raise awareness about the harsh reality of pediatric brain tumors as we continue our efforts to initiate an international clinical trial that will assess the efficacy of our lead compound, volasertib, in treating brain cancers like medulloblastoma and DIPG.

📢 Exciting News Alert!

We are thrilled to announce that our CEO and Co-Founder, Ricardo Garcia, has been featured in the book "TOP Disruptors - Guide to Entrepreneurs and CEOs Who Stand Out for Their Innovative Talent".

This esteemed publication meticulously selects 1,000 Spanish entrepreneurs and CEOs who have demonstrated exceptional leadership and a disruptive approach over the past year. It delves into the profiles of emerging visionaries whose innovative ideas are set to continue revolutionizing industries.

We extend our heartfelt thanks to Top Comunicación & RR.PP. for recognizing Ricardo's visionary leadership.

ℹ https://www.topcomunicacion.com/disruptivos-top-guia-empresarios-ceos-innovadores/

We're thrilled to share that Oncoheroes Biosciences has achieved 86% commitment in our current $1M investment round through Capital Cell.

Join Oncoheroes' co-founders, Ricardo Garcia and Cesare Spadoni, in a final webinar where they will unveil an investment opportunity with a dual impact: saving lives and delivering substantial returns.

Dive into a market brimming with untapped potential.

Date: Tuesday, April 16th
Time: 12 pm EST / 6 pm CET

Register here:
https://tinyurl.com/m7xzt93y

Exciting News!

We're thrilled to announce that Oncoheroes Biosciences, has been selected as one of the eleven finalists for the inaugural J.P. Morgan Asset Management: Life Sciences Innovation Summit!

Scheduled for May 14th–15th, 2024, at the Cleveland Clinic Abu Dhabi, this event aims to cultivate a thriving ecosystem for early-stage entrepreneurs in the life sciences sector.

During the event, Cesare Spadoni, Oncoheroes' Co-Founder, will present the company's pioneering work to a panel of judges comprising industry leaders and investors, including Glimcher, President and CEO at the Dana-Farber Cancer Institute, Jorge A. Guzman, MD, MBA, CEO at Cleveland Clinic Abu Dhabi, Shahrukh Hashmi, Director of Research at the Department of Health, Abu Dhabi, David Hung, M.D., President and CEO at Nuvation Bio, Yasmine Hayek Kobeissi Ph.D, Executive Director at Blue Horizon Advisors, and Anya Schiess, Managing Partner at J.P. Morgan Life Sciences Private Capital.

This recognition underscores Oncoheroes Biosciences' unwavering commitment to advancing novel treatments for childhood cancers.

https://oncoheroes.com/insights-news-1/20240410/ohfnlstjpmad

📢 Incredible news!

We're thrilled to announce that the Super Sam Foundation: Fighting Childhood Cancer has generously awarded Oncoheroes Biosciences with a grant, marking the second occasion the foundation has supported our mission. Their initial investment in June 2020 played a pivotal role in preparing our lead compound, volasertib, for clinical trials. Now, with this funding, we're excited to leverage the foundation's support to launch the clinical trial of volasertib, bringing us closer to advancing cancer therapeutics.

“We're once again thrilled to partner with the team to continue our support for volasertib. This drug is full-circle for our Foundation, as we wish our Founding Hero, Sam, would have had this option during his fight 10 years ago. We deeply appreciate the incredible work Oncoheroes is doing in the childhood cancer community and excited to support their vital work,” stated Cassie Santhuff, president and co-founder of the Super Sam Foundation.

A huge thank you to the Super Sam Foundation: Fighting Childhood Cancer for their unwavering dedication to our cause 🎗

https://oncoheroes.com/insights-news-1/20240409/supersamfoundation

📢 Breaking news!

We're excited to share that Oncoheroes Biosciences has achieved a significant milestone in pediatric oncology research, by engineering a screening platform designed to minimize toxicity risks and advance molecules with the highest likelihood of efficacy and safety for patients.

Cesare Spadoni, Oncoheroes’ Chief Operating Officer and co-founder elaborates, "The development of this platform is step forward in our quest to accelerate pediatric oncology drug development. By prioritizing safety and efficacy, we aim to accelerate the translation of scientific discoveries into life-saving therapies."

Our paper, published in Society for Laboratory Automation and Screening journal, highlights our commitment to advancing treatments for medulloblastoma. Explore the impact of our work and join us in making a difference for young patients.

https://tinyurl.com/y4wmtf9c

Oncoheroes Biosciences is proud to share that we're the recipient of a new grant by the Teen Board of The Caroline Symmes Children's Cancer Endowment. This new support will be directed to back the launch of an international clinical trial to test our lead-compound, volasertib.

"We are thrilled to be supporting Oncoheroes on their journey of becoming a global leader in delivering new pediatric oncology drugs, as they perfectly align with our mission to raise crucial funds to support cutting edge research” stated Lara Rahman, Teen Board President.

Thanks Caroline Symmes Children’s Cancer Endowment and welcome to the Oncoheroes' family!

🔗 https://oncoheroes.com/insights-news-1/20240402/carolinesymmes

Oncoheroes Biosciences Oncoheroes is a biotech company 100% focused on advancing new therapies for childhood cancer

📢 Exciting Announcement!

We're beyond thrilled to join forces with Brittney’s Believers , founded by Elena and Brian Bliss in loving memory of their daughter, Brittney Gail Bliss.

Brittney’s Believers is dedicated to raising funds and awareness for childhood cancer research, and they are now supporting Oncoheroes Biosciences by providing a grant that will fuel the launch of the international clinical trial to test the efficacy of our lead-compound, volsertib, in five types of pediatric cancer, including rhabdomyosarcoma.

“We decided to partner with Oncoheroes because they are at the forefront in fighting childhood cancer! The work they are doing aligns with our mission in hopes of finding new and better ways to treat and one day defeat childhood cancer!” stated Elena, Brittney’s mom.

Thanks Brittney’s Believers for joining our mission! 🎗

https://oncoheroes.com/insights-news-1/20240325/brittneysbelievers

❔ How do you live a cancer diagnosis as a child? How is life after treatment? Albert Ananyan and Richi Garcia Puig, two young childhood cancer survivors shared their experiences with cancer at the by OncoDaily.

In a session led by Derek Lynch, volunteer at the Richi Foundation, Albert and Richi bravely recounted the treatments they endured and the profound impact childhood cancer had on their lives. Despite the adversity they faced, both are now pursuing their dreams with passion and determination.

💬 Albert, reflecting on his journey, shared, "life is full of challenges, but that's its beauty." His words encapsulate the spirit of resilience that has driven him forward. Richi, on the brink of his junior year at Framingham University, offered inspiring advice to fellow survivors, urging them to embrace their dreams and live life to the fullest. "Find your passion and pursue it relentlessly," he emphasized.

For those seeking further insight into their compelling stories, the full session can be accessed through the link below. Don't miss out, and remember to subscribe, as more captivating sessions from the series will be shared soon.

Courage in the Face of Cancer: Albert and Richi's Stories | Oncothon 2024 This session took place during the , a 24-hour streaming event by Oncodaily organised to raise awareness and funds for childhood cancer research...

🎉 Exciting news!

Oncoheroes Biosciences is honored to be the recipient of a grant from Rally Foundation for Childhood Cancer Research. This grant will play a crucial role in launching the international clinical trial to test the efficacy of our lead-compound, volasertib.

💬 As she announced the grant, Dean Crowe, CEO and founder of Rally Foundation for Childhood Cancer Research, stated:

“Rally’s Medical Advisory Board recognizes the promise of this international clinical trial and Oncoheroes’ lead compound that targets five different pediatric cancers. We are encouraged that this trial will bring hope to children and adolescents fighting cancer”.

A heartfelt thank you to Rally Foundation for their continued support in the fight against pediatric cancer.

ℹ https://oncoheroes.com/insights-news-1/20240227/rallygrant

❔ Did you know childhood cancer is classified as a rare disease, yet it's the first leading cause of death by disease among children in developed countries?

Shockingly, there are only seven drugs specifically approved for pediatric oncology, with many kids still receiving outdated adult cancer treatments.
Why? Because pediatric cancer research often takes a back seat to adult cancers, lacking the funding and attention it desperately needs.

This , we're shedding light on the urgent need for innovative treatments tailored to children. At Oncoheroes Biosciences, we're committed to changing this narrative, developing safer, more effective therapies for childhood cancer.

Together, let's make a difference in the lives of these brave young fighters.